Do analysts recommend AEON or BIAF?

AEON Biopharma presently has a consensus target price of $1.10, suggesting a potential upside of 331.88%. Given AEON Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to AEON or BIAF?

In the previous week, bioAffinity Technologies had 6 more articles in the media than AEON Biopharma. MarketBeat recorded 7 mentions for bioAffinity Technologies and 1 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.43 indicating that AEON Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral bioAffinity Technologies 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, CNTX or AEON?

Context Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A AEON Biopharma N/A N/A -$36.63M -$4.42 N/A

Is CNTX or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% AEON Biopharma N/A N/A -994.63%

Does the media prefer CNTX or AEON?

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AEON or MDXH more profitable?

AEON Biopharma has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% MDxHealth -33.46% N/A -24.25%

Does the media favor AEON or MDXH?

In the previous week, AEON Biopharma and AEON Biopharma both had 1 articles in the media. AEON Biopharma's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RADX or AEON?

Radiopharm Theranostics has higher revenue and earnings than AEON Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 16.54 -$24.83M N/A N/A AEON Biopharma N/A N/A -$36.63M -$4.42 N/A

Is RADX or AEON more profitable?

Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A AEON Biopharma N/A N/A -994.63%

Does the media prefer RADX or AEON?

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 1 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AEON or ATNM more profitable?

AEON Biopharma's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Actinium Pharmaceuticals N/A -100.85% -47.89%

AEON Biopharma (AEON) Competitors

$0.25 -0.02 (-6.01%)

As of 09/3/2026 04:00 PM Eastern

Compare

AEON vs. BIAF, CNTX, MDXH, RADX, and ATNM

Should you buy AEON Biopharma stock or one of its competitors? AEON Biopharma's main competitors and comparable companies include bioAffinity Technologies (BIAF), Context Therapeutics (CNTX), MDxHealth (MDXH), Radiopharm Theranostics (RADX), and Actinium Pharmaceuticals (ATNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AEON Biopharma compare to bioAffinity Technologies?

AEON Biopharma (NASDAQ:AEON) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

AEON Biopharma has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, indicating that its share price is 211% less volatile than the broader market.

In the previous week, bioAffinity Technologies had 6 more articles in the media than AEON Biopharma. MarketBeat recorded 7 mentions for bioAffinity Technologies and 1 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.43 indicating that AEON Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AEON Biopharma presently has a consensus target price of $1.10, suggesting a potential upside of 331.88%. Given AEON Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

bioAffinity Technologies has higher revenue and earnings than AEON Biopharma. bioAffinity Technologies is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
bioAffinity Technologies	$6.16M	1.22	-$14.91M	-$109.45	N/A

AEON Biopharma has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. AEON Biopharma's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Summary

AEON Biopharma beats bioAffinity Technologies on 11 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Context Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

AEON Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
AEON Biopharma	N/A	N/A	-994.63%

Context Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 1,598.81%. AEON Biopharma has a consensus target price of $1.10, suggesting a potential upside of 331.88%. Given Context Therapeutics' higher probable upside, equities analysts clearly believe Context Therapeutics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Context Therapeutics beats AEON Biopharma on 6 of the 11 factors compared between the two stocks.

How does AEON Biopharma compare to MDxHealth?

AEON Biopharma (NASDAQ:AEON) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, AEON Biopharma and AEON Biopharma both had 1 articles in the media. AEON Biopharma's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has higher revenue and earnings than AEON Biopharma. MDxHealth is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

AEON Biopharma presently has a consensus target price of $1.10, indicating a potential upside of 331.88%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 198.36%. Given AEON Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe AEON Biopharma is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

AEON Biopharma has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

AEON Biopharma has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
MDxHealth	-33.46%	N/A	-24.25%

Summary

AEON Biopharma beats MDxHealth on 6 of the 11 factors compared between the two stocks.

How does AEON Biopharma compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Radiopharm Theranostics currently has a consensus target price of $11.00, indicating a potential upside of 411.63%. AEON Biopharma has a consensus target price of $1.10, indicating a potential upside of 331.88%. Given Radiopharm Theranostics' higher possible upside, research analysts plainly believe Radiopharm Theranostics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Radiopharm Theranostics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 1 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Radiopharm Theranostics has higher revenue and earnings than AEON Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	16.54	-$24.83M	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

Summary

Radiopharm Theranostics beats AEON Biopharma on 5 of the 9 factors compared between the two stocks.

How does AEON Biopharma compare to Actinium Pharmaceuticals?

AEON Biopharma (NASDAQ:AEON) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

AEON Biopharma currently has a consensus price target of $1.10, suggesting a potential upside of 331.88%. Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 376.19%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

AEON Biopharma's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

AEON Biopharma has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

In the previous week, AEON Biopharma had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for AEON Biopharma and 0 mentions for Actinium Pharmaceuticals. AEON Biopharma's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
Actinium Pharmaceuticals	Neutral

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AEON Biopharma has higher earnings, but lower revenue than Actinium Pharmaceuticals. AEON Biopharma is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Actinium Pharmaceuticals	$35.09M	0.94	-$48.82M	$0.36	2.92

Summary

AEON Biopharma beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AEON vs. The Competition

Export

Metric	AEON Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.71M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	1.42	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-0.06	16.29	12.89	6.14
Net Income	-$36.63M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-18.94%	0.34%	0.60%	-0.27%
1 Month Performance	-13.95%	8.52%	5.73%	0.68%
1 Year Performance	-66.82%	52.66%	25.35%	14.84%

AEON Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEON AEON Biopharma	3.4309 of 5 stars	$0.25 -6.0%	$1.10 +331.9%	-68.6%	$12.71M	N/A	1.42	5	Gap Up
BIAF bioAffinity Technologies	0.7195 of 5 stars	$5.19 -10.8%	N/A	-88.5%	$42.09M	$6.16M	N/A	10	News Coverage Gap Down
CNTX Context Therapeutics	2.4763 of 5 stars	$0.44 -6.4%	$6.17 +1,316.3%	-56.9%	$40.00M	N/A	N/A	7	Gap Up High Trading Volume
MDXH MDxHealth	2.018 of 5 stars	$0.79 +6.4%	$2.17 +174.7%	-79.8%	$39.04M	$114.02M	N/A	300	Gap Up
RADX Radiopharm Theranostics	2.3415 of 5 stars	$2.48 +1.6%	$11.00 +343.5%	-60.9%	$35.86M	$2.35M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AEON Biopharma (AEON) Competitors

AEON vs. BIAF, CNTX, MDXH, RADX, and ATNM

How does AEON Biopharma compare to bioAffinity Technologies?

Summary

How does AEON Biopharma compare to Context Therapeutics?

Summary

How does AEON Biopharma compare to MDxHealth?

Summary

How does AEON Biopharma compare to Radiopharm Theranostics?

Summary

How does AEON Biopharma compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AEON Biopharma (AEON) Competitors

AEON vs. BIAF, CNTX, MDXH, RADX, and ATNM

How does AEON Biopharma compare to bioAffinity Technologies?

Which has more risk & volatility, AEON or BIAF?

Does the media refer more to AEON or BIAF?

Do insiders and institutionals hold more shares of AEON or BIAF?

Do analysts recommend AEON or BIAF?

Which has higher valuation and earnings, AEON or BIAF?

Is AEON or BIAF more profitable?

Summary

How does AEON Biopharma compare to Context Therapeutics?

Which has better earnings & valuation, CNTX or AEON?

Is CNTX or AEON more profitable?

Which has more risk & volatility, CNTX or AEON?

Does the media prefer CNTX or AEON?

Do analysts rate CNTX or AEON?

Do institutionals and insiders hold more shares of CNTX or AEON?

Summary

How does AEON Biopharma compare to MDxHealth?

Do institutionals & insiders have more ownership in AEON or MDXH?

Does the media favor AEON or MDXH?

Which has stronger earnings and valuation, AEON or MDXH?

Do analysts prefer AEON or MDXH?

Which has more risk & volatility, AEON or MDXH?

Is AEON or MDXH more profitable?

Summary

How does AEON Biopharma compare to Radiopharm Theranostics?

Is RADX or AEON more profitable?

Do analysts prefer RADX or AEON?

Which has more volatility and risk, RADX or AEON?

Does the media prefer RADX or AEON?

Do insiders and institutionals believe in RADX or AEON?

Which has better valuation and earnings, RADX or AEON?

Summary

How does AEON Biopharma compare to Actinium Pharmaceuticals?

Do analysts rate AEON or ATNM?

Is AEON or ATNM more profitable?

Which has more volatility and risk, AEON or ATNM?

Does the media favor AEON or ATNM?

Do insiders and institutionals hold more shares of AEON or ATNM?

Which has preferable earnings & valuation, AEON or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools